Edition:
United Kingdom

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

612.30INR
11:29am BST
Change (% chg)

Rs8.20 (+1.36%)
Prev Close
Rs604.10
Open
Rs606.00
Day's High
Rs614.95
Day's Low
Rs595.40
Volume
2,213,334
Avg. Vol
2,299,060
52-wk High
Rs696.60
52-wk Low
Rs325.15

Chart for

About

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  BION.NS Industry Sector
P/E (TTM): -- 85.69 32.76
EPS (TTM): -- -- --
ROI: -- 1.78 14.61
ROE: -- 3.28 16.33

CORRECTED-India's Biocon June-qtr profit jumps 47 pct, beats estimates

July 26 India's Biocon Ltd reported a 47 percent rise in June-quarter profit on Thursday, helped by higher income from its biologics and research services businesses.

26 Jul 2018

FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market, with U.S. health regulators approving its version of the infection-fighting treatment.

04 Jun 2018

UPDATE 2-FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

* Mylan shares up 5.2 pct, Amgen down 1.7 pct after market (Adds analyst comment, updates shares)

04 Jun 2018

FDA approves Mylan's biosimilar to Neulasta

June 4 The U.S. Food And Drug Administration on Monday approved a drug from Mylan NV as the first biosimilar to Amgen's drug Neulasta to help reduce the risk of infection during cancer treatment.

04 Jun 2018

BRIEF-India's Biocon Says USFDA, European Regulator Issue Observations On Bangalore Plant

* SAYS US-FDA COMPLETED PRE-APPROVAL INSPECTION OF STERILE DRUG PRODUCT PLANT IN BANGALORE AND ISSUED A FORM 483 WITH 7 OBSERVATIONS

02 May 2018

BRIEF-Biocon Q4 Net Profit Up 2 Percent

* Q4 NET PROFIT UP 2 PERCENT TO 1.30 BILLION RUPEES; Q4 TOTAL REVENUE 12.37 BILLION RUPEES VERSUS 9.74 BILLION RUPEES YEAR-AGO Further company coverage: (Reuters.Briefs@thomsonreuters.com)

26 Apr 2018

India's Biocon Q4 profit rises 2.2 pct

April 26 Biocon Ltd, India's biggest biotechnology company, posted a marginal 2.2 percent rise in net profit on Thursday.

26 Apr 2018

BRIEF-Mylan, Biocon Seek To Accelerate Introduction Of Adalimumab Biosimilar In EU

* MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU Source text - https://bit.ly/2IIPzM6 Further company coverage:

11 Apr 2018

BRIEF-Mylan, Biocon get approvals from European Commission, TGA Australia for Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE APPROVALS FROM THE EUROPEAN COMMISSION AND TGA AUSTRALIA FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE Source text for Eikon: Further company coverage:

28 Mar 2018

Earnings vs. Estimates

No consensus analysis data available.